Literature DB >> 1739411

Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms.

U Fuhr1, J Doehmer, N Battula, C Wölfel, C Kudla, Y Keita, A H Staib.   

Abstract

Primary steps in the metabolism of caffeine and theophylline are cleavage of methyl groups and/or hydroxylation at position 8, mediated by cytochromes P450. V79 Chinese hamster cells genetically engineered for stable expression of single forms of rat cytochromes P450IA1, P450IA2 and P450IIBI and human P450IA2 and rat liver epithelial cells expressing murine P450IA2 were used to overcome problems arising in the proper allocation of metabolic pathways to specific isoforms by conventional techniques. These cell lines were exposed to caffeine and/or theophylline, and concentrations of metabolites formed in the medium were determined by HPLC. Caffeine was metabolized by human, rat and murine P450IA2, resulting in the formation of four primary demethylated and hydroxylated metabolites. However, there were differences in the relative amounts of the metabolites. The human and the mouse P450IA2 isoforms predominantly mediated 3-demethylation of caffeine. The rat cytochrome P450IA2 mediated both 3-demethylation and 1-demethylation of caffeine to a similar extent. Theophylline was metabolized mainly via 8-hydroxylation. All cell lines tested were able to carry out this reaction, with highest activities in cell lines expressing rat or human P450IA2, or rat P450IA1. These results support the hypothesis that caffeine plasma clearance is a specific in vivo probe for determining human P450IA2 activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1739411     DOI: 10.1016/0006-2952(92)90282-n

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  18 in total

Review 1.  Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin.

Authors:  J F Westphal
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

2.  Drug-phytochemical interactions.

Authors:  Costas Ioannides
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

Review 3.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

4.  Biotransformation of caffeine by cDNA-expressed human cytochromes P-450.

Authors:  H R Ha; J Chen; S Krahenbuhl; F Follath
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 5.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

6.  Lack of an effect of nefazodone on the pharmacokinetics and pharmacodynamics of theophylline during concurrent administration in patients with chronic obstructive pulmonary disease.

Authors:  R C Dockens; D Rapoport; D Roberts; D S Greene; R H Barbhaiya
Journal:  Br J Clin Pharmacol       Date:  1995-12       Impact factor: 4.335

7.  Three-dimensional modelling of human cytochrome P450 1A2 and its interaction with caffeine and MeIQ.

Authors:  J J Lozano; E López-de-Briñas; N B Centeno; R Guigó; F Sanz
Journal:  J Comput Aided Mol Des       Date:  1997-07       Impact factor: 3.686

Review 8.  Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance.

Authors:  U Fuhr
Journal:  Drug Saf       Date:  1998-04       Impact factor: 5.606

9.  Metabolism of theophylline by cDNA-expressed human cytochromes P-450.

Authors:  H R Ha; J Chen; A U Freiburghaus; F Follath
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

10.  Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man.

Authors:  U Fuhr; K Klittich; A H Staib
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.